These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38031670)

  • 21. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear Imaging for the Assessment of Cardiotoxicity from Chemotherapeutic Agents in Oncologic Disease.
    Sreenivasan J; Hooda U; Ranjan P; Jain D
    Curr Cardiol Rep; 2021 May; 23(6):65. PubMed ID: 33961140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced imaging modalities to detect cardiotoxicity.
    Awadalla M; Hassan MZO; Alvi RM; Neilan TG
    Curr Probl Cancer; 2018 Jul; 42(4):386-396. PubMed ID: 30297038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of cardiovascular magnetic resonance imaging in cardio-oncology.
    Saunderson CED; Plein S; Manisty CH
    Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):383-396. PubMed ID: 33404058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Multimodality Cardiac Imaging in Patients Undergoing Cancer Treatment.
    Wengrofsky P; Feldman S
    Curr Cardiol Rep; 2023 Jan; 25(1):1-8. PubMed ID: 36527535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
    Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
    Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer.
    Grazziotin LR; Picon PD
    J Oncol Pharm Pract; 2017 Jun; 23(4):264-272. PubMed ID: 26983449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac Imaging Methods for Chemotherapy-related Cardiotoxicity Screening and Related Radiation Exposure: Current Practice and Trends.
    Kolla BC; Roy SS; Duval S; Weisdorf D; Valeti U; Blaes A
    Anticancer Res; 2017 May; 37(5):2445-2449. PubMed ID: 28476812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.
    Hong YJ; Park HS; Park JK; Han K; Park CH; Kim TK; Yoo SJ; Lee JY; Kim PK; Hur J; Lee HJ; Kim YJ; Suh YJ; Paek MY; Choi BW
    Sci Rep; 2017 Jun; 7(1):2663. PubMed ID: 28572614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
    Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
    BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
    Jerusalem G; Lancellotti P; Kim SB
    Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiparametric cardiac magnetic resonance unveiling the mechanisms and early manifestations of anticancer drug cardiotoxicity.
    Francone M; Figliozzi S; Monti L; Loewe C; Catapano F
    Eur Radiol; 2023 Dec; 33(12):8439-8441. PubMed ID: 37464110
    [No Abstract]   [Full Text] [Related]  

  • 37. The Role of Cardiac MRI in Animal Models of Cardiotoxicity: Hopes and Challenges.
    Park CJ; Branch ME; Vasu S; Meléndez GC
    J Cardiovasc Transl Res; 2020 Jun; 13(3):367-376. PubMed ID: 32248349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
    J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
    Nakano S; Takahashi M; Kimura F; Senoo T; Saeki T; Ueda S; Tanno J; Senbonmatsu T; Kasai T; Nishimura S
    Cardiol J; 2016; 23(3):270-80. PubMed ID: 27173679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook.
    Chianca M; L'Abbate S; Fabiani I; Aimo A; Emdin M; Passino C; Fedele A; Cipolla CM; Cardinale DM
    Expert Opin Drug Metab Toxicol; 2023 Feb; 19(2):109-119. PubMed ID: 36989398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.